MAUREE A. GINGRICH, MEMBER
101ST LEGISLATIVE DISTRICT

LEGISLATIVE OFFICE
430 IRVIS OFFICE BUILDING
PO BOX 202101
HARRISBURG, PA 17120-2101
PHONE: (717) 783-1815
FAX: (717) 705-2569

DISTRICT OFFICE
445 WEST PENN AVENUE
CLEONA SQUARE
CLEONA, PA 17042
PHONE: (717) 270-1905
FAX: (717) 270-1854

MGINGRIC@PAHOUSEGOP.COM

House of Representatives
COMMONWEALTH OF PENNSYLVANIA
HARRISBURG

COMMITTEES

AGING & OLDER ADULT SERVICES
MINORITY CHAIRMAN – SUBCOMMITTEE ON PROGRAMS AND BENEFITS
APPROPRIATIONS
HEALTH AND HUMAN SERVICES
MINORITY CHAIRMAN – SUBCOMMITTEE ON HUMAN SERVICES
LOCAL GOVERNMENT
DEPUTY WHIP

LOCAL GOVERNMENT COMMISSION

December 20, 2010

U.S. Food and Drug Administration
Center for Drug Evaluation and Research
10903 New Hampshire Avenue
Silver Spring, MD 20993

Dear U.S. Food and Drug Administration:

Our office has been made aware of concerns regarding Levaquin and other fluoroquinolone antibiotics. We hope that you will consider adopting further safety warnings concerning this class of antibiotics. Our office is not requesting that these drugs be removed from the market. We are asking that both physicians and the public have proper and adequate warnings on the potential long term chronic adverse effects from fluoroquinolone antibiotics. Our concern lies with a gentleman who was prescribed Levaquin which he claims failed to fully note the dangerous side effects, thus, leaving him now to live and cope with various health problems. He brought to our office published articles by medical doctors on severe adverse reactions to Levaquin. Should you have any specific questions relating to this gentleman's experience, below is his contact information:

John Fratti
1562 Macintosh Way
Hummelstown, PA 17036

Adverse reactions from this class of antibiotics can leave people with prolonged and permanent disabilities. Consumers deserve the right of informed consent and better disclosure of the risks involved.

In order to alert both physicians and patients, we request the FDA adopt the following safety measures concerning fluoroquinolone antibiotics.

Place a boxed warning on the label to reflect the possible long term neurological disorders associated with this class of antibiotics.